BMN 110 US Expanded Access Program

Status:

APPROVED_FOR_MARKETING

BMN 110 US Expanded Access Program

Lead Sponsor:

BioMarin Pharmaceutical

Conditions:

Mucopolysaccharidosis IVA

Morquio A Syndrome

Eligibility:

All Genders

Brief Summary

The Expanded Access Program (EAP) is an open-label, multicenter program to: 1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial pro...

Eligibility Criteria

Inclusion

Diagnosed with MPS IVA as confirmed by either N-acetylgalactosamine-6-sulfatase (GALNS) enzymatic test (GALNS activity in affected range, beta-galactosidase and a second lysosomal sulfatase activity within normal range) or molecular diagnostic test (two mutations in GALNS identified that have previously been associated with an enzyme defect).
Willing and able to provide written, signed informed consent, or in the case of patients under the age of 18, provide written assent (as required by the IRB) and written informed consent by a legally authorized representative after the nature of the program has been explained, and prior to any program assessments or evaluations.
Sexually active patients must be willing to use an acceptable method of contraception while participating in the program.
Females of childbearing potential must have a negative pregnancy test at Baseline and be willing to have additional pregnancy tests during the program.
Willing and able to comply with all program procedures.

Exclusion

Pregnant or breastfeeding at Baseline or planning to become pregnant (self or partner) at any time during the program. Patients who become pregnant during the program will be discontinued from the program.
Currently enrolled in an ongoing clinical study of BMN 110.
Discontinued from a BMN 110 clinical study secondary to a safety-related event.
Use of any investigational product (other than BMN 110 in a clinical study) or investigational medical device within 30 days prior to Baseline, or requirement for any investigational agent prior to completion of all scheduled program assessments.
Not a current US resident or expecting to have travel plans outside the US during the planned period of participation in the Expanded Access Program (EAP) that may interfere with dosing regimen, scheduled program visits and safety monitoring.
Any condition that, in the view of the Investigator or sponsor, places the patient at high risk of poor treatment compliance or of not completing the EAP.

Key Trial Info

Start Date :

Trial Type :

EXPANDED_ACCESS

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01858103

Last Update

April 2 2014

Active Locations (25)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (25 locations)

Birmingham, Alabama, United States, 35294

Little Rock, Arkansas, United States, 72202